OPTR Related Analyst Ratings
-
Oppenheimer Upgrades Optimer Pharmaceuticals (OPTR) to Outperform
-
Ladenburg Thalmann Downgrades Optimer Pharmaceuticals (OPTR) to Neutral
-
Oppenheimer Downgrades Optimer Pharmaceuticals (OPTR) to Perform
-
ThinkEquity Downgrades Optimer Pharmaceuticals (OPTR) to Accumulate
-
Baird Downgrades Optimer Pharmaceuticals (OPTR) to Neutral
-
Needham Upgrades Optimer Pharmaceuticals (OPTR) to Buy
-
Optimer Pharma (OPTR) Stock Slips on Numerous Analyst Downgrades
-
Ladenburg Thalmann Initiates Coverage on Optimer Pharmaceuticals (OPTR) with a Buy
-
ThinkEquity Initiates Coverage on Optimer Pharmaceuticals (OPTR) with a Buy
-
Oppenheimer Starts Optimer Pharma (OPTR) at Outperform
-
Canaccord Adams Reiterates 'Buy' Rating on Optimer Pharmaceuticals (OPTR), Raises Price Target
-
Rodman & Renshaw Assumes Coverage on Optimer Pharmaceuticals (OPTR)
-
Susquehanna Initiates Coverage on Optimer Pharmaceuticals (OPTR) with a Neutral
-
Baird Initiates Coverage on Optimer Pharmaceuticals (OPTR) with a Neutral
-
Needham Starts Optimer Pharmaceuticals (OPTR) at Buy
-
Jefferies & Co Initiates Coverage on Optimer Pharmaceuticals (OPTR) with a Buy
Back to OPTR Stock Lookup
